RVL PHARMACEUTICALS PLC (RVLP) Fundamental Analysis & Valuation

NASDAQ:RVLP • IE00BF2HDL56

Current stock price

0.0282 USD
-0.01 (-32.05%)
At close:
0.0223 USD
-0.01 (-20.92%)
After Hours:

This RVLP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RVLP Profitability Analysis

1.1 Basic Checks

  • In the past year RVLP has reported negative net income.
  • In the past year RVLP has reported a negative cash flow from operations.
RVLP Yearly Net Income VS EBIT VS OCF VS FCFRVLP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -100M -200M

1.2 Ratios

  • With a Return On Assets value of -79.93%, RVLP is not doing good in the industry: 74.88% of the companies in the same industry are doing better.
  • The Return On Equity of RVLP (-418.14%) is worse than 80.68% of its industry peers.
Industry RankSector Rank
ROA -79.93%
ROE -418.14%
ROIC N/A
ROA(3y)-35.52%
ROA(5y)-35.76%
ROE(3y)-90.19%
ROE(5y)-107.06%
ROIC(3y)N/A
ROIC(5y)N/A
RVLP Yearly ROA, ROE, ROICRVLP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 -50 -100 -150 -200

1.3 Margins

  • The Gross Margin of RVLP (74.73%) is better than 81.64% of its industry peers.
  • RVLP's Gross Margin has improved in the last couple of years.
  • RVLP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y10.54%
RVLP Yearly Profit, Operating, Gross MarginsRVLP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. RVLP Health Analysis

2.1 Basic Checks

  • RVLP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RVLP has been increased compared to 1 year ago.
  • The debt/assets ratio for RVLP is higher compared to a year ago.
RVLP Yearly Shares OutstandingRVLP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
RVLP Yearly Total Debt VS Total AssetsRVLP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M

2.2 Solvency

  • RVLP has an Altman-Z score of -11.70. This is a bad value and indicates that RVLP is not financially healthy and even has some risk of bankruptcy.
  • RVLP has a worse Altman-Z score (-11.70) than 80.68% of its industry peers.
  • RVLP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.00, RVLP perfoms like the industry average, outperforming 59.90% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.7
ROIC/WACCN/A
WACC8%
RVLP Yearly LT Debt VS Equity VS FCFRVLP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M 200M 300M 400M

2.3 Liquidity

  • RVLP has a Current Ratio of 0.38. This is a bad value and indicates that RVLP is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of RVLP (0.38) is worse than 94.20% of its industry peers.
  • RVLP has a Quick Ratio of 0.38. This is a bad value and indicates that RVLP is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of RVLP (0.36) is worse than 93.24% of its industry peers.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.36
RVLP Yearly Current Assets VS Current LiabilitesRVLP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RVLP Growth Analysis

3.1 Past

  • RVLP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.84%, which is quite impressive.
  • RVLP shows a small growth in Revenue. In the last year, the Revenue has grown by 5.64%.
  • RVLP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -27.35% yearly.
EPS 1Y (TTM)27.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.43%
Revenue 1Y (TTM)5.64%
Revenue growth 3Y-40.83%
Revenue growth 5Y-27.35%
Sales Q2Q%-2.25%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.87% on average over the next years. This is a very strong growth
  • RVLP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.00% yearly.
EPS Next Y27.9%
EPS Next 2Y25.51%
EPS Next 3Y20.95%
EPS Next 5Y25.87%
Revenue Next Year-28.9%
Revenue Next 2Y1.31%
Revenue Next 3Y13%
Revenue Next 5Y34%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RVLP Yearly Revenue VS EstimatesRVLP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
RVLP Yearly EPS VS EstimatesRVLP Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. RVLP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RVLP. In the last year negative earnings were reported.
  • Also next year RVLP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVLP Price Earnings VS Forward Price EarningsRVLP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVLP Per share dataRVLP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • RVLP's earnings are expected to grow with 20.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.51%
EPS Next 3Y20.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RVLP Dividend Analysis

5.1 Amount

  • RVLP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

RVLP Fundamentals: All Metrics, Ratios and Statistics

RVL PHARMACEUTICALS PLC

NASDAQ:RVLP (10/20/2023, 8:09:06 PM)

After market: 0.0223 -0.01 (-20.92%)

0.0282

-0.01 (-32.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14
Earnings (Next)11-08
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.54%
Ins Owner Change0%
Market Cap3.14M
Revenue(TTM)36.92M
Net Income(TTM)-68.27M
Analysts82.22
Price Target3.21 (11282.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-54.08%
Min EPS beat(2)-108.96%
Max EPS beat(2)0.8%
EPS beat(4)2
Avg EPS beat(4)-29.3%
Min EPS beat(4)-108.96%
Max EPS beat(4)1.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-16.02%
Min Revenue beat(2)-23.76%
Max Revenue beat(2)-8.29%
Revenue beat(4)0
Avg Revenue beat(4)-14.9%
Min Revenue beat(4)-23.76%
Max Revenue beat(4)-3.83%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.81%
PT rev (3m)-1.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.04%
EPS NY rev (1m)2.76%
EPS NY rev (3m)-30.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-51.29%
Revenue NY rev (1m)5.95%
Revenue NY rev (3m)-23.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.09
P/FCF N/A
P/OCF N/A
P/B 0.19
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0.33
BVpS0.15
TBVpS-0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.93%
ROE -418.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.73%
FCFM N/A
ROA(3y)-35.52%
ROA(5y)-35.76%
ROE(3y)-90.19%
ROE(5y)-107.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y10.54%
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 804.97%
Cap/Sales 8.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.36
Altman-Z -11.7
F-Score3
WACC8%
ROIC/WACCN/A
Cap/Depr(3y)79.08%
Cap/Depr(5y)49.88%
Cap/Sales(3y)4.49%
Cap/Sales(5y)3.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.43%
EPS Next Y27.9%
EPS Next 2Y25.51%
EPS Next 3Y20.95%
EPS Next 5Y25.87%
Revenue 1Y (TTM)5.64%
Revenue growth 3Y-40.83%
Revenue growth 5Y-27.35%
Sales Q2Q%-2.25%
Revenue Next Year-28.9%
Revenue Next 2Y1.31%
Revenue Next 3Y13%
Revenue Next 5Y34%
EBIT growth 1Y36.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.55%
EBIT Next 3Y33.43%
EBIT Next 5Y26.37%
FCF growth 1Y31.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.92%
OCF growth 3YN/A
OCF growth 5YN/A

RVL PHARMACEUTICALS PLC / RVLP Fundamental Analysis FAQ

What is the fundamental rating for RVLP stock?

ChartMill assigns a fundamental rating of 2 / 10 to RVLP.


Can you provide the valuation status for RVL PHARMACEUTICALS PLC?

ChartMill assigns a valuation rating of 1 / 10 to RVL PHARMACEUTICALS PLC (RVLP). This can be considered as Overvalued.


What is the profitability of RVLP stock?

RVL PHARMACEUTICALS PLC (RVLP) has a profitability rating of 2 / 10.